Burden of Nonsteroidal Anti-inflammatory and Antiplatelet Drug Use in Asia: A Multidisciplinary Working Party Report

Clinical Gastroenterology and Hepatology

Volumn 10, Issue 7, 2012, Pages 753-760

  Chan, Francis Ka leung ^a   Goto, Shinya ^b   Wu, Ming Shiang ^c   Abola, Maria Teresa B ^d   Yeoh, Khay Guan ^e   Sutrisna, Bambang ^f   Chua, Siew Siang ^g   Mahachai, Varocha ^h   Turajane, Thana ⁱ   Wu, Brian ^j   Zeng, Qing Yu ^k   Sugano, Kentaro ^l  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b Institute for Advanced Medical Research   (Japan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d UNIVERSITY OF THE PHILIPPINES   (Philippines)

^e Dept Medicine Endocrinol Diabet   (Singapore)

^f UNIVERSITY OF INDONESIA   (Indonesia)

^g UNIVERSITY OF MALAYA   (Malaysia)

^h CHULALONGKORN UNIVERSITY   (Thailand)

ⁱ Arthritis Foundation   (Thailand)

^j Wujing General Hospital   (China)

^k THE FIRST AFFILIATED HOSPITAL OF SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^l JICHI MEDICAL UNIVERSITY   (Japan)

more..

Author keywords

Bleeding; Coronary; Stroke; Ulcer

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; HISTAMINE H2 RECEPTOR ANTAGONIST; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; REBAMIPIDE; SUCRALFATE; TICLOPIDINE;

ARTICLE; ASIA; CEREBROVASCULAR ACCIDENT; CHINESE MEDICINE; CLINICAL PROTOCOL; CONSENSUS DEVELOPMENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; EVIDENCE BASED MEDICINE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TOXICITY; GASTROINTESTINAL TRACT; HIGH RISK PATIENT; HUMAN; LIVER TOXICITY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL PAIN; NECK PAIN; PEPTIC ULCER; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; RATING SCALE; RISK REDUCTION; THROMBOSIS; UPPER GASTROINTESTINAL BLEEDING;

ANTI-INFLAMMATORY AGENTS; ASIA; ATHEROSCLEROSIS; DRUG UTILIZATION; HUMANS; MUSCULOSKELETAL DISEASES; PLATELET AGGREGATION INHIBITORS; PREVALENCE;

EID: 84862657042     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.03.027     Document Type: Article

References (71)

1. Sung J., Russell R.I., Yeomans N., et al. Non-steroidal anti-inflammatory drug toxicity in the upper gastrointestinal tract. J Gastroenterol Hepatol 2000, 15(Suppl):G58-G68.
2. Atkins D., Best D., Briss P.A., et al. Grading quality of evidence and strength of recommendations. BMJ 2004, 328:1490.
3. Symmons D., Mathers C., Pfleger B. Global burden of osteoarthritis in the year 2000 2003, World Health Organization, Geneva, Switzerland.
4. Health in Asia and the Pacific. Chapter 6: Burden of disease 2008, 177-194. World Health Organization Regional Offices for South-East Asia and the Western Pacific, World Health Organization, Geneva, Switzerland.
5. Chen Y.F., Jobanputra P., Barton P., et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2008, 12:1-278. iii.
6. Sakamoto C., Soen S. Efficacy and safety of the selective cyclooxygenase-2 inhibitor celecoxib in the treatment of rheumatoid arthritis and osteoarthritis in Japan. Digestion 2011, 83:108-123.
7. Chan F.K., Ching J.Y., Hung L.C., et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005, 352:238-244.
8. Weiner D.K., Ernst E. Complementary and alternative approaches to the treatment of persistent musculoskeletal pain. Clin J Pain 2004, 20:244-255.
9. Cui X., Trinh K., Wang Y.J. Chinese herbal medicine for chronic neck pain due to cervical degenerative disc disease. Cochrane Database Syst Rev 2010, 1. CD006556.
10. Kubo M., Kiyohara Y., Kato I., et al. Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study. Stroke 2003, 34:2349-2354.
11. Tuomilehto J., Morelos S., Yason J., et al. Trends in cardiovascular diseases mortality in the Philippines. Int J Epidemiol 1984, 13:168-176.
12. Yang G., Kong L., Zhao W., et al. Emergence of chronic non-communicable diseases in China. Lancet 2008, 372:1697-1705.
13. Schooling C.M., Lau E.W., Tin K.Y., et al. Social disparities and cause-specific mortality during economic development. Soc Sci Med 2010, 70:1550-1557.
14. Chung R.Y., Schooling C.M., Cowling B.J., et al. How does socioeconomic development affect risk of mortality. Am J Epidemiol 2010, 171:345-356.
15. Bhatt D.L., Eagle K.A., Ohman E.M., et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 2010, 304:1350-1357.
16. Singh R.B., Suh I.L., Singh V.P., et al. Hypertension and stroke in Asia: prevalence, control and strategies in developing countries for prevention. J Hum Hypertens 2000, 14:749-763.
17. Principal causes of death Ministry of Health, Singapore, Accessed June 4, 2010. http://www.moh.gov.sg/content/moh_web/home/statistics/Health_Facts_Singapore/Principal_Causes_of_Death.html.
18. Philippines death and DALY estimates, 2002 Accessed June, 2010. http://apps.who.int/healthinfo/global_burden_disease/estimates_regional/en/index.html.
19. Venketasubramanian N. The epidemiology of stroke in ASEAN countries: a review. Neurol J Southeast Asia 1998, 3:9-14.
20. Zhao D., Liu J., Wang W., et al. Epidemiological transition of stroke in China: twenty-one-year observational study from the Sino-MONICA-Beijing Project. Stroke 2008, 39:1668-1674.
21. Wong K.S. Risk factors for early death in acute ischemic stroke and intracerebral hemorrhage: a prospective hospital-based study in Asia-Asian Acute Stroke Advisory Panel. Stroke 1999, 30:2326-2330.
22. Steg P.G., Bhatt D.L., Wilson P.W., et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007, 297:1197-1206.
23. Khor G.L. Cardiovascular epidemiology in the Asia-Pacific region. Asia Pac J Clin Nutr 2001, 10:76-80.
24. Yeo T.C., Chan Y.H., Low L.P., et al. Risk factor profile and treatment patterns of patients with atherothrombosis in Singapore: insight from the REACH registry. Ann Acad Med Singapore 2008, 37:365-371.
25. Yamazaki T., Goto S., Shigematsu H., et al. Prevalence, awareness and treatment of cardiovascular risk factors in patients at high risk of atherothrombosis in Japan. Circ J 2007, 71:995-1003.
26. Ogawa H., Nakayama M., Morimoto T., et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008, 300:2134-2141.
27. Ootani H., Iwakiri R., Shimoda R., et al. Role of Helicobacter pylori infection and nonsteroidal anti-inflammatory drug use in bleeding peptic ulcers in Japan. J Gastroenterol 2006, 12:41-46.
28. Ong T.Z., Hawkey C.J., Ho K.Y. Nonsteroidal anti-inflammatory drug use is a significant cause of peptic ulcer disease in a tertiary hospital in Singapore: a prospective study. J Clin Gastroenterol 2006, 40:795-800.
29. Hung L.C., Ching J.Y., Sung J.J., et al. Long-term outcome of Helicobacter pylori-negative idiopathic bleeding ulcers: a prospective cohort study. Gastroenterology 2005, 128:1845-1850.
30. Papatheodoridis G.V., Sougioultzis S., Archimandritis A.J. Effects of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: a systematic review. Clin Gastroenterol Hepatol 2006, 4:130-142.
31. Huang J.Q., Sridhar S., Hunt R.H. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002, 359:14-22.
32. Chan F.K., Sung J.J., Chung S.C., et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997, 350:975-979.
33. Chan F.K., To K.F., Wu J.C., et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 2002, 359:9-13.
34. Vergara M., Catalán M., Gisbert J.P., et al. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005, 21:1411-1418.
35. Leontiadis G.I., Sreedharan A., Dorward S., et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess 2007, 11:iii-iv. 1-164.
36. Niculescu L., Li C., Huang J., et al. Pooled analysis of GI tolerability of 21 randomized controlled trials of celecoxib and nonselective NSAIDs. Curr Med Res Opin 2009, 25:729-740.
37. Leung W.K., Bjarnason I., Wong V.W., et al. Small bowel enteropathy associated with chronic low-dose aspirin therapy. Lancet 2007, 369:614.
38. Watanabe T., Sugimori S., Kameda N., et al. Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostol: a pilot study. Clin Gastroenterol Hepatol 2008, 6:1279-1282.
39. Sturkenboom M.C., Burke T.A., Dieleman J.P., et al. Underutilization of preventive strategies in patients receiving NSAIDs. Rheumatology (Oxford) 2003, 42(Suppl 3):iii23-iii31.
40. Targownik L.E., Metge C.J., Leung S. Underutilization of gastroprotective strategies in aspirin users at increased risk of upper gastrointestinal complications. Aliment Pharmacol Ther 2008, 28:88-96.
41. Abraham N.S., Hartman C., Castillo D., et al. Effectiveness of national provider prescription of PPI gastroprotection among elderly NSAID users. Am J Gastroenterol 2008, 103:323-332.
42. Lanas A., Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin 2007, 23:163-173.
43. Lai K.C., Lam S.K., Chu K.M., et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002, 346:2033-2038.
44. Lanas A., García-Rodríguez L.A., Arroyo M.T., et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006, 55:1731-1738.
45. Diener H.C., Bogousslavsky J., Brass L.M., et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004, 364:331-337.
46. Mak K.H., Bhatt D.L., Shao M., et al. Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study. Am Heart J 2009, 157:658-665.
47. Fukuuchi Y., Tohgi H., Okudera T., et al. A randomized, double-blind study comparing the safety and efficacy of clopidogrel versus ticlopidine in Japanese patients with noncardioembolic cerebral infarction. Cerebrovasc Dis 2008, 25:40-49.
48. Hooper L., Brown T.J., Elliott R., et al. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ 2004, 329:948.
49. Targownik L.E., Metge C.J., Leung S., et al. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs. Gastroenterology 2008, 134:937-944.
50. Höer A., Gothe H., Schiffhorst G., et al. Comparison of the effects of diclofenac or other non-steroidal anti-inflammatory drugs (NSAIDs) and diclofenac or other NSAIDs in combination with proton pump inhibitors (PPI) on hospitalization due to peptic ulcer disease. Pharmacoepidemiol Drug Saf 2007, 16:854-858.
51. Pang S.H., Leung W.K., Graham D.Y. Ulcers and gastritis. Endoscopy 2008, 40:136-139.
52. Chan F.K., Chung S.C., Suen B.Y., et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001, 344:967-973.
53. Chan F.K., Hung L.C., Suen B.Y., et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002, 347:2104-2110.
54. Lai K.C., Chu K.M., Hui W.M., et al. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med 2005, 118:1271-1278.
55. Taha A.S., Hudson N., Hawkey C.J., et al. Famotidine for the prevention of gastric and duodenal ulcers caused by non-steroidal anti-inflammatory drugs. N Engl J Med 1996, 334:1435-1439.
56. Lanas A., Bajador E., Serrano P., et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 2000, 343:834-839.
57. Singh G., Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 1999, 26(Suppl):18-24.
58. Hawkey C.J., Talley N.J., Scheiman J.M., et al. Maintenance treatment with esomeprazole following initial relief of non-steroidal anti-inflammatory drug-associated upper gastrointestinal symptoms: the NASA2 and SPACE2 studies. Arthritis Res Ther 2007, 9:R17.
59. Laheij R.J., Van Rossum L.G., Jansen J.B., et al. Proton-pump inhibitor therapy for acetylsalicylic acid associated upper gastrointestinal symptoms: a randomized placebo-controlled trial. Aliment Pharmacol Ther 2003, 18:109-115.
60. Hawkey C.J., Jones R.H., Yeomans N.D., et al. Efficacy of esomeprazole for resolution of symptoms of heartburn and acid regurgitation in continuous users of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2007, 25:813-821.
61. Chan F.K., Lanas A., Scheiman J., et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010, 376:173-179.
62. Chan F.K., Wong V.W., Suen B.Y., et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 2007, 369:1621-1626.
63. Miglioli M., Bianchi Porro G., Vaira D., et al. Prevention with sucralfate gel of NSAID-induced gastroduodenal damage in arthritic patients. Am J Gastroenterol 1996, 91:2367-2371.
64. Malagelada J.R., Rodríguez de la Serna A., Dammann H.G., et al. Sucralfate therapy in NSAID bleeding gastropathy. Clin Gastroenterol Hepatol 2003, 1:51-56.
65. Ono S., Kato M., Imai A., et al. Preliminary trial of rebamipide for prevention of low-dose aspirin-induced gastric injury in healthy subjects: a randomized, double-blind, placebo-controlled, cross-over study. J Clin Biochem Nutr 2009, 45:248-253.
66. Bhatt D.L., Scheiman J., Abraham N.S., et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008, 52:1502-1517.
67. Yeomans N., Lanas A., Labenz J., et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol 2008, 103:2465-2473.
68. Yun K.H., Rhee S.J., Park H.Y., et al. Effect of omeprazole on the antiplatelet activity of clopidogrel. Int Heart J 2010, 51:13-16.
69. Sibbing D., Morath T., Stegherr J., et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009, 101:714-719.
70. Kwok C.S., Loke Y.K. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther 2010, 31:810-823.
71. Bhatt D.L., Cryer B.L., Contant C.F., et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010, 363:1909-1917.